CJC-1295 DAC

CJC-1295 is a peptide drug that stimulates growth hormone production and forms long-lasting conjugates with plasma proteins.; Conjugated CJC-1295 is difficult to detect by mass spectrometry due to low abundance and high molecular weight.; The new LC-MS/MS method successfully confirmed CJC-1295 after immuno-affinity capture and tryptic digestion.; The method detected CJC-1295 at concentrations as low as 180 pg/mL in equine plasma.

CJC-1295 covalently links to plasma proteins via a maleimidopropionic acid group, evading standard mass spectrometry detection.; The I-PCR assay detects the CJC-1295-protein conjugate at concentrations as low as 0.8 pg/mL.; A screening threshold of 50 pg/mL was established to differentiate CJC-1295 from endogenous equine GHRH.; The assay effectively identified CJC-1295 in equine plasma samples after administration to thoroughbred race horses.

Forum users were well versed in poly-use of performance and image drug supplementation.; Reasons for using CJC-1295 included weight loss, muscle enhancement, youthful skin, improved sleep, and injury healing.; Concerns focused on female-specific consequences due to gender variations in growth hormone pulses affecting dosage and cycling.; Public health interventions should address female self-medicating use of synthetic growth hormone and related adverse health consequences.

The preparation contained a 29 amino acid peptide with a C-terminal amide.; The peptide sequence matched CJC-1295, a growth-hormone-releasing factor.; CJC-1295 is listed as a Prohibited Substance under Section S2 of the WADA Prohibited List.; The substance has potential performance-enhancing effects and is available for illicit use.

Two protein spots decreased after treatment: apolipoprotein A1 isoform and transthyretin isoform.; Three protein spots increased after treatment: beta-hemoglobin, a C-terminal albumin fragment, and a mix of immunoglobulin and albumin fragments.; A linear relationship was found between the spot containing immunoglobulin and albumin fragments and IGF-1 levels.; Identified proteins may serve as potential biomarkers for GH and/or IGF-1 activity.

Daily CJC-1295 normalized body weight and length in GHRHKO mice.; Every 48- or 72-hour dosing improved growth but did not fully normalize it.; Femur and tibia length were normal with daily and every-48-hour treatment.; CJC-1295 increased pituitary RNA and GH mRNA, indicating somatotroph proliferation.

GH pulsatility was preserved after CJC-1295 administration, with unaltered pulse frequency and magnitude.; Basal (trough) GH levels increased 7.5-fold, contributing to a 46% increase in mean GH and 45% increase in IGF-I.; No significant differences were observed between 60 and 90 µg/kg doses.; IGF-I increases did not correlate with any parameters of GH secretion.

Single CJC-1295 injection increased GH 2- to 10-fold for ≥6 days and IGF-I 1.5- to 3-fold for 9-11 days.; Estimated half-life of CJC-1295 was 5.8-8.1 days.; Multiple doses maintained IGF-I above baseline for up to 28 days with cumulative effects.; No serious adverse reactions; doses of 30 or 60 μg/kg were safe and well tolerated.

What is CJC-1295 DAC?

CJC-1295 with Drug Affinity Complex (DAC) is a synthetic analog of growth hormone-releasing hormone (GHRH) engineered to extend its half-life via covalent attachment to a drug affinity complex (DAC), which binds to serum albumin. This modification allows for sustained, multi-day release of the peptide, resulting in pro

How does CJC-1295 DAC work?

Albumin-binding (DAC) GHRH analog producing sustained, multi-day elevation of GH and IGF-1.

What is the research status of CJC-1295 DAC?

CJC-1295 DAC is currently classified as discontinued, with 32 research references on record. This is for research purposes only and is not medical advice.

What is the half-life of CJC-1295 DAC?

The reported half-life of CJC-1295 DAC is 6-8 days.